中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

1型肝肾综合征患者内毒素和内皮素1水平分析

高宝秀 聂鑫 贺勇 杨正兵 罗通行 宋昊岚 李贵星

引用本文:
Citation:

1型肝肾综合征患者内毒素和内皮素1水平分析

DOI: 10.3969/j.issn.1001-5256.2014.01.016
基金项目: 

四川省科技支撑项目(2010SZ0252); 

详细信息
  • 中图分类号: R575.2

Analysis of endotoxin and endothelin-1 levels in patients with type 1 hepatorenal syndrome

Research funding: 

 

  • 摘要:

    目的分析肝硬化腹水伴1型肝肾综合征(HRS)患者的临床资料、实验室指标、感染发生率、血清降钙素原(PCT)和内皮素1(ET-1)水平,探讨内毒素和ET-1在HRS发生中的作用。方法纳入本院2009年1月至2012年10月住院的肝硬化腹水伴1型HRS患者56例(HRS组)及肝硬化伴腹水且肾功能正常患者60例(非HRS组),收集2组患者的一般资料、肝硬化病因、感染发生率及类型、Child-Pugh分级、全身炎症反应综合征(SIRS)评分及平均动脉压(MAP);同时采集2组患者血液,分析肝肾功能、电解质、PCT、ET-1水平。比较2组患者的临床资料和检测指标。计数资料采用χ2检验,正态分布计量资料组间比较采用成组t检验,非正态分布计量资料组间比较采用Wilcoxon秩和检验。结果 HRS组感染发生率为75.0%,显著高于非HRS组的28.4%(χ2=11.91,P<0.05)。HRS组PCT、ET-1和SIRS分别为8.72(3.14,31.68)ng/L、(13.04±2.82)pg/ml和2.1±1.1,高于非HRS组的0.11(0.04,0.45)ng/L、(5.76±1.68)...

     

  • [1]WONG F.Hepatorenal syndrome:current management[J].Curr Gastroenterol Rep, 2008, 10 (1) :22-29.
    [2]ANGELI P, MERKEL C.Pathogenesis and management of hepatorenal syndrome in patients with cirrhosis[J].J Hepatol, 2008, 42 (Suppl 1) :s93-s103.
    [3]ZHANG HQ, NIE X, WU B, et al.Correlation of endotoxin and hepatorenal syndrome in patients with decompensated liver cirrhosis[J].J Clin Hepatol, 2012, 15 (6) :539-541. (in Chinese) 张焕强, 聂鑫, 吴斌, 等.内毒素血症与肝肾综合征的关系研究[J].实用肝脏病杂志, 2012, 15 (6) :539-541.
    [4]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B[J].J Clin Hepatol, 2006, 22 (1) :3-15. (in Chinese) 中华医学会肝病学分、感染病学分会.慢性乙型肝炎防治指南[J].临床肝胆病杂志, 2006, 22 (1) :3-15.
    [5] SALERNO F, GERBES A, GINS P, et al.Diagnosis, prevention and treatment of hepatorenal syndrome with cirrhosis[J].Gut, 2007, 56 (9) :1310-1318.
    [6] GARCIA-PAGN JC, CACA K, BUREAU C, et al.Early use of TIPS in patients with cirrhosis and variceal bleeding[J].N Engl J Med, 2010, 362 (25) :2370-2379.
    [7]CRDENAS A, GINES P.Hepatorenal syndrome[J].Clin Liver Dis, 2006, 10 (2) :371-385.
    [8]WEN Y, WANG DL, LIU P.Activated protein kinase C alpha participates in the decreased glomerular filtration rate in hepatorenal syndrome induced by tumor necrosis factor alpha[J].J Med Res, 2013, 42 (3) :120-123. (in Chinese) 闻颖, 王冬蕾, 刘沛.蛋白激酶Cα激活参与肿瘤坏死因子α引起的肝肾综合征肾小球滤过率下降[J].医学研究杂志, 2013, 42 (3) :120-123.
    [9]KRAG A, BENDTSEN F, HENRIKSEN JH, et al.Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites[J].Gut, 2010, 59 (1) :105-110.
    [10]MOORE KP, AITHAL GP.Guidelines on the management of ascites in cirrhosis[J].Gut, 2006, 55 (Suppl 6) :vi1-2.
    [11]RUNYON BA.AASLD Practice Guidelines Committee.Management of adult patients with ascites due to cirrhosis:an update[J].Hepatology, 2009, 49 (6) , 2087-2107.
    [12] European Association for the Study of the Liver.EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J].J Hepatology, 2010, 53 (3) , 397-417.
    [13]HARBARTH S, HOLECKOVA K, FROIDEVAUX C, et al.Diagnostic value of procalcitonin, interleukin-6 and interleukin-8 in critically ill patients admitted with suspected sepsis[J].Am J Respire Crit Care Med, 2001, 164 (3) :396-402.
    [14]XU XY, ZHENG YY.Hepatorenal syndrome-vasoconstrictor or vasodilator?[J].J Clin Hepatol, 2011, 27 (8) :801-803. (in Chinese) 徐小元, 郑颖颖.肝肾综合征——缩血管还是扩血管?[J].临床肝胆病杂志, 2011, 27 (8) :801-803.
    [15] GINSP, SCHRIER RW.Renal failure in cirrhosis[J].N Engl J Med, 2009, 361 (13) :1279-1290.
    [16]TURBAN S, THULUVATH PJ, ATTA MG.Hepatorenal syndrome[J].World J Gastroenterol, 2007, 13 (30) :4046-4055.
    [17]THABUT D, MASSARD J, GANGLOFF A, et al.Model for endstage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure[J].Hepatology, 2007, 46 (6) :1872-1882.
    [18]GAO BX, NIE X, WU B, et al.Implications of elevated levels of prostagtandin I2 and thromboxane A2 in type I Hepatorenal syndrome[J].J Clin Hepatol, 2012, 28 (11) :860-862. (in Chinese) 高宝秀, 聂鑫, 吴斌, 等.Ⅰ型肝肾综合征患者前列腺素I2和血栓素A2水平分析[J].临床肝胆病杂志, 2012, 28 (11) :860-862.
    [19]FENHAMMAR J, ANDERSSON A, FORESTIER J, et al.Endothelin receptor a antagonism attenuates renal medullary blood flow impairment in endotoxemic pigs[J].PLoS ONE, 2011, 6 (7) :e21534.
    [20]DIVINO JN, CHAWLA KS, da SILA CM, et al.Endothelin-1production by the canine macrophage cell line DH82:Enhanced production in response to microbial challenge[J].Vet Immunol Immunopathol, 2010, 136 (1-2) :127-132.
    [21]HOSHINO K, TAKEUCHI O, KAWAI T, et al.Cutting edge:Toll-like receptor 4 (TLR4) -deficient mice are hyporesponsive to lipopolysaccharide:evidence for TLR4 as the Lps gene product[J].J Immunol, 1999, 162 (7) :3749-3752.
    [22]SAWAL H, UEDAL T, TAKEYAMA Y, et al.Role of toll-like receptor 4 in the pathophysiology of severe acute pancreatitis in mice[J].Surg Today, 2007, 37 (10) :867-873.
    [23]RAKONCZAY Z Jr, HEGYI P, TAKCS T, et al.The role of NF-kB activation in the pathogenesis of acute pancreatitis[J].Gut, 2008, 57 (2) :259-267.
  • 加载中
计量
  • 文章访问数:  2542
  • HTML全文浏览量:  16
  • PDF下载量:  764
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-05-13
  • 出版日期:  2014-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回